Premium
P2‐141: BRAIN‐DERIVED NEUROTROPHIC FACTOR (BDNF) POLYMORPHISMS ARE ASSOCIATED WITH DIFFERENTIAL RATES OF AMYLOID ACCUMULATION AND COGNITIVE DECLINE IN COGNITIVELY NORMAL OLDER ADULTS
Author(s) -
Acosta Jazmin,
Geda Yonas E.,
Stokin Gorazd B.,
Fleisher Adam S.,
Reschke Cole,
Bauer Robert J.,
Thiyyagura Pradeep,
Lu Bai,
Caselli Richard J.,
Weiner Michael,
Reiman Eric M.,
Chen Kewei
Publication year - 2014
Publication title -
alzheimer's and dementia
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 6.713
H-Index - 118
eISSN - 1552-5279
pISSN - 1552-5260
DOI - 10.1016/j.jalz.2014.05.816
Subject(s) - psychology , standardized uptake value , neuropsychology , brain derived neurotrophic factor , hippocampal formation , neuroimaging , oncology , medicine , neuroscience , positron emission tomography , audiology , cognition , neurotrophic factors , receptor
patients whowere performed with biomarker PET PiB and cognitive, neurological and psychiatric assessment. Patients with absence of beta-amyloid deposition -PiB negative status(n 1⁄4 64) was separated, and the presumptive diagnoses reevaluated, according to DSM IV diagnostic criteria, presenting symptoms, neurocognitive assessment, and correlations with functional neuroimaging PET with FDG. Results: Of the 64 patients who had PiB negative status with cognitive or behavioral nonspecific presenting symptoms 40 patients (62.5%) continued with amnestic MCI diagnoses (23%), non-amnestic MCI (17%), and normal cognition (23%) without dementia or other diagnoses. Four patients (6.25%) were diagnosed as DTA, 3 patients (4.68%) were diagnosed as FTD, and 4 (6.25%) were APP. Five patients (8%) had a final diagnosis of depression, and 1 in bipolar disorder. Conclusions: Beyond AD, the PiB biomarker may be useful in the diagnostic workup of patients with cognitive / behavioral symptoms. The absence of amyloid can add a new element for guiding the clinician in the diagnostic context of each case.